FOXO4-DRI

ID: foxo4_dri

Aliases: FOX04, FOX04-DRI, FOXO4 D-retro-inverso peptide, FOXO4 peptide

Type: compound

Route/form: preclinical/research peptide; no approved human route

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: in_vitro, preclinical

Linked sources: 2

Broad outcomes: Hormones / fertility / sexual health, Longevity / mitochondrial / redox, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• FOXO4-p53 interaction disruption hypothesis
• senescent cell apoptosis
• SASP reduction

Optimization domains

• longevity
• senolytic
• aging
• hormones
• joint health

Research basis

• Preclinical and human-cell studies support a senolytic mechanism for FOXO4-DRI in selected models.
• Aged-mouse Leydig-cell work is directly relevant to endocrine-aging claims seen in communities.

Limits, risks, and missing evidence

• No mature human anti-aging efficacy base.
• Senescent-cell biology can be context-dependent, and blanket senolysis may not be benign.

Risk flags

• preclinical only
• senolytic context
• unknown long term safety
• unapproved context

Linked papers, labels, and reviews

1. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
   preclinical / pubmed_foxo4dri_leydig_2020
   Aged-mouse endocrine senolytic rationale for FOXO4-DRI.
2. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes
   in_vitro / pubmed_foxo4dri_chondrocytes_2021
   Human-cell senolytic support; no direct anti-aging clinical evidence.